Praxis pauses vormatrigine study after trial misses primary endpoint
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Comstock Resources signs $1.65B deal with SOCAR, $450M JV
Praxis Precision Medicines Provides Vormatrigine Program Update
June 1, 2026 4:15 PM EDTPOWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure
Secondary measure, the 50% response rate, was met and seizure reduction during the second half of the study on higher dose (30 mg) was more pronounced
Vormatrigine was generally well-tolerated; adverse event-related discontinuations were less than 10%
Approximately 90% of patients from the vormatrigine arm transitioned to and remain in the open label extension (OLE) study
Praxis is pausing enrollment in the POWER2 study to reassess the vormatrigine program and... More
